Q3 2024 Adaptive Biotechnologies Corp Earnings Call Transcript
Key Points
- MRD revenue increased by 52% year-over-year, driven by both clinical and pharma sectors.
- Medicare set a new gapfill rate of $2,007 for the clonoSEQ test, a 17% increase from the previous rate.
- Operating expenses declined by 11% compared to the previous year, showcasing effective cost management.
- Sequencing gross margin improved by 6 percentage points due to workflow efficiencies.
- The company raised the lower end of its MRD revenue guidance due to strong year-to-date performance.
- Immune medicine revenue decreased by 32% from the previous year, primarily due to a decrease in Genentech upfront amortization.
- The company took a $1.8 million reserve charge related to aged claims from 2023, impacting ASP growth.
- Despite strong MRD growth, the upper end of the MRD revenue guidance was not increased, indicating potential uncertainties.
- There is potential for volatility in pharma revenue due to the timing of study completions and regulatory milestones.
- The company reported a net loss of $32.1 million for the quarter, highlighting ongoing financial challenges.
Good day and welcome to Adaptive Biotechnologies third quarter financial results. (Operator Instructions) As a reminder, this call may be recorded. I would like to turn the call over to Karina Calzadilla, Head of Investor Relations. Please go ahead.
Thank you, Michelle. Good afternoon, everyone. I would like to welcome you to Adaptive Biotechnologies third quarter 2024 earnings conference call. Earlier today, we issued a press release reporting Adaptive financial results for the third quarter of '24. The press release is available at www.adaptivebiotech.com. We are conducting a live webcast of this call and will be referencing to a slide presentation that has been posted to the investor section or corporate website.
During the call, management will make projections and other forward-looking statements within the meaning of federal security laws regarding future events and the future financial
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
